Innovations in oral gene delivery: challenges and potentials

Page, David T P; Cudmore, Sally

doi:10.1016/s1359-6446(00)01600-7

Cited by 36 publications

(21 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Local expression of therapeutic proteins may have therapeutic benefit in the treatment of inflammatory bowel disease, intestinal cancer, and the intestinal symptoms of cystic fibrosis (O' Neill et al 2011) (Page and Cudmore 2001). Furthermore, the intestine can potentially provide a route of entry into the bloodstream for locally expressed therapeutic proteins such as Factor VIII in haemophilia patients (Bowman et al 2008), or indeed for gene therapies to distant disease sites.…”

Section: Introductionmentioning

confidence: 99%

“…Enterocytes present useful targets for certain gene therapy strategies, since, given the underlying rich blood supply, transfected enterocytes could be utilised as "protein factories" where the expressed therapeutic protein is secreted into the bloodstream (Page and Cudmore 2001). Furthermore, locally expressed proteins may have therapeutic potential in the treatment of intestinal diseases (e.g.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mechanistic studies on the uptake and intracellular trafficking of novel cyclodextrin transfection complexes by intestinal epithelial cells

Neill

Guo

Byrne

et al. 2011

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Mechanistic studies on the uptake and intracellular trafficking of novel cyclodextrin transfection complexes by intestinal epithelial cells

Neill

Guo

Byrne

et al. 2011

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…However, the delivery system must protect the pDNA from pH variation and enzymatic degradation in the GIT. Therefore, the design of robust non-viral delivery systems can lead to successful oral gene delivery (Boussif et al, 1995;Page & Cudmore, 2001;Garinot et al, 2007;Wang et al, 2012). Different polymers like chitosan, Poly-L-Lysine, pectin can be used for oral gene delivery (Krishnendu et al, 1999;Kwoh et al, 1999;Liu & Yao, 2002;Howarda et al, 2004;Guliyeva et al, 2006;Bhavsar & Amiji, 2007;Plapied et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer

Bhatt¹,

Khatri²,

Kumar³

et al. 2014

Drug Delivery

View full text Add to dashboard Cite

This study was aimed to develop and evaluate p53 polyplex-loaded enteric-coated calcium pectinate microbeads for oral gene delivery as an effective novel alternative for colorectal cancer therapy. Mutation in p53 is the key event in colorectal cancer (CRC) and an important target for the treatment of CRC through gene therapy. Polymethacrylates-based non-viral vectors were evaluated for their ability to complex, protect and transfect p53 (wt) into colon cancer cell line. Polyplexes were formulated by complexation of cationic polymer with anionic pDNA at different N/P ratios. p53 polyplex-loaded calcium pectinate (CP) microbeads were prepared by ionotropic gelation of pectin with calcium chloride and coated with Eudragit Õ S100. In vitro release studies showed that enteric-coated CP microbeads protected the release of p53 polyplex in upper GIT with less than 10% release. In-vitro cell line studies and in vivo studies in rat showed that polymethacrylate carrier could transfect the pDNA effectively. Results of in vivo gene expression study further confirmed the ability of enteric-coated calcium pectinate microbeads to deliver pDNA specifically to rat colon. Conclusively, enteric-coated calcium pectinate microbeads released p53 polyplex specifically in colon and could serve as an effective alternative for CRC therapy.

show abstract

“…can be also used, especially for short-term applications. 4 Another option is the use of bacterial delivery systems called bactofection. 5 Every vector system has its own strengths and weaknesses that are summarized in Table 1.…”

Section: Introductionmentioning

confidence: 99%

Bacteria in gene therapy: bactofection versus alternative gene therapy

et al. 2005

View full text Add to dashboard Cite

Recent advances in gene therapy can be attributed to improvements of gene delivery vectors. New viral and nonviral transport vehicles that considerably increase the efficiency of transfection have been prepared. However, these vectors still have many disadvantages that are difficult to overcome, thus, a new approach is needed. The approach of bacterial delivery could in the future be important for gene therapy applications. In this article we try to summarize the most important modifications that are used for the preparation of applied strains, difficulties that are related with bacterial gene delivery and the current use of bactofection in animal experiments and clinical trials. Important differences to the alternative gene therapy (AGT) are discussed. AGT resembles bacteria-mediated protein delivery, as the therapeutical proteins are produced not by host cells but by the bacteria in situ and the expression can be regulated exogenously. Although the procedure of bacterial gene delivery is far from being definitely solved, bactofection remains a promising technique for transfection in human gene therapy.

show abstract

Innovations in oral gene delivery: challenges and potentials

Cited by 36 publications

References 73 publications

Mechanistic studies on the uptake and intracellular trafficking of novel cyclodextrin transfection complexes by intestinal epithelial cells

Mechanistic studies on the uptake and intracellular trafficking of novel cyclodextrin transfection complexes by intestinal epithelial cells

Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer

Bacteria in gene therapy: bactofection versus alternative gene therapy

Contact Info

Product

Resources

About